Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice
The human milk fat globule membrane protein BA46 (lactadherin) is highly overexpressed in human breast tumors, making it a potential target for tumor immunotherapy. We have identified BA46-derived peptides that contain the motif recognized by the MHC class I molecule HLA-A2.1 and that are processed and presented by human breast carcinoma cells. In mice lacking normal class I molecules but expressing an HLA-A2.1/D(b)-beta2 microglobulin single chain (HHD mice), three peptides elicited specific CTL activity. Two of these peptides also stimulated cytotoxic activity in peripheral blood lymphocytes from HLA-A2.1-positive breast carcinoma patients. Adoptive transfer of HHD-derived bulk CTLs to nude mice bearing human breast carcinoma transplants reduced tumor growth. These peptides therefore represent naturally processed BA46-derived CTL epitopes that can be used in peptide-based antitumor vaccines.
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2002 |
---|---|
Erschienen: |
2002 |
Enthalten in: |
Zur Gesamtaufnahme - volume:110 |
---|---|
Enthalten in: |
The Journal of clinical investigation - 110(2002), 4 vom: 21. Aug., Seite 453-62 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Carmon, Lior [VerfasserIn] |
---|
Anmerkungen: |
Date Completed 06.09.2002 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM120493810 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM120493810 | ||
003 | DE-627 | ||
005 | 20231222191017.0 | ||
007 | tu | ||
008 | 231222s2002 xx ||||| 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0402.xml |
035 | |a (DE-627)NLM120493810 | ||
035 | |a (NLM)12189239 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Carmon, Lior |e verfasserin |4 aut | |
245 | 1 | 0 | |a Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1/D(b)-beta2m transgenic mice |
264 | 1 | |c 2002 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a Date Completed 06.09.2002 | ||
500 | |a Date Revised 13.11.2018 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The human milk fat globule membrane protein BA46 (lactadherin) is highly overexpressed in human breast tumors, making it a potential target for tumor immunotherapy. We have identified BA46-derived peptides that contain the motif recognized by the MHC class I molecule HLA-A2.1 and that are processed and presented by human breast carcinoma cells. In mice lacking normal class I molecules but expressing an HLA-A2.1/D(b)-beta2 microglobulin single chain (HHD mice), three peptides elicited specific CTL activity. Two of these peptides also stimulated cytotoxic activity in peripheral blood lymphocytes from HLA-A2.1-positive breast carcinoma patients. Adoptive transfer of HHD-derived bulk CTLs to nude mice bearing human breast carcinoma transplants reduced tumor growth. These peptides therefore represent naturally processed BA46-derived CTL epitopes that can be used in peptide-based antitumor vaccines | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antigens, Surface |2 NLM | |
650 | 7 | |a Cell Extracts |2 NLM | |
650 | 7 | |a Epitopes |2 NLM | |
650 | 7 | |a HLA-A2 Antigen |2 NLM | |
650 | 7 | |a MFGE8 protein, human |2 NLM | |
650 | 7 | |a Mfge8 protein, mouse |2 NLM | |
650 | 7 | |a Milk Proteins |2 NLM | |
650 | 7 | |a Neoplasm Proteins |2 NLM | |
650 | 7 | |a Peptides |2 NLM | |
650 | 7 | |a RNA, Neoplasm |2 NLM | |
650 | 7 | |a beta 2-Microglobulin |2 NLM | |
700 | 1 | |a Bobilev-Priel, Irene |e verfasserin |4 aut | |
700 | 1 | |a Brenner, Baruch |e verfasserin |4 aut | |
700 | 1 | |a Bobilev, Dimitry |e verfasserin |4 aut | |
700 | 1 | |a Paz, Adrian |e verfasserin |4 aut | |
700 | 1 | |a Bar-Haim, Erez |e verfasserin |4 aut | |
700 | 1 | |a Tirosh, Boaz |e verfasserin |4 aut | |
700 | 1 | |a Klein, Tirza |e verfasserin |4 aut | |
700 | 1 | |a Fridkin, Mati |e verfasserin |4 aut | |
700 | 1 | |a Lemonnier, Francois |e verfasserin |4 aut | |
700 | 1 | |a Tzehoval, Esther |e verfasserin |4 aut | |
700 | 1 | |a Eisenbach, Lea |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t The Journal of clinical investigation |d 1924 |g 110(2002), 4 vom: 21. Aug., Seite 453-62 |w (DE-627)NLM000005487 |x 1558-8238 |7 nnns |
773 | 1 | 8 | |g volume:110 |g year:2002 |g number:4 |g day:21 |g month:08 |g pages:453-62 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 110 |j 2002 |e 4 |b 21 |c 08 |h 453-62 |